市場調查報告書
商品編碼
879184

表皮成長因子受體(EGFR)抑制劑 - 全球市場預測(2017年-2026年)

Epidermal Growth Factor Receptor (EGFR) Inhibitors - Global Market Outlook (2017-2026)

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 162 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球表皮成長因子受體(EGFR)抑制劑市場在2017年估算為19億1,000萬美元的規模。在2017年∼2026年間預測將以11.2%的年複合成長率成長,2026年達到49億6,000萬美元的規模。

本報告提供全球表皮成長因子受體(EGFR)抑制劑市場的相關調查,市場機會和成長及阻礙因素,各適應症、阻斷劑、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 簡介

第3章 市場趨勢分析

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 新興市場
  • 今後的市場情況

第4章 波特的五力分析

  • 供應商談判力
  • 買主談判力
  • 替代品的威脅
  • 新加入廠商的威脅
  • 產業內的競爭

第5章 全球表皮成長因子受體(EGFR)抑制劑市場:各適應症

  • 簡介
  • 乳癌
  • 大腸癌症
  • 肺癌症
  • 其他

第6章 全球表皮成長因子受體(EGFR)抑制劑市場:各阻斷劑

  • 簡介
  • 單株抗體
    • Cetuximab
    • Necitumumab
  • 蛋白酪氨酸激酶抑制劑(TKI)
    • Erlotinib
    • Gefitinib

第7章 全球表皮成長因子受體(EGFR)抑制劑市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他
  • 中東及非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他

第8章 市場主要趨勢

  • 契約,聯盟,合作及合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴張
  • 其他主要策略

第9章 企業分析

  • Amgen Inc
  • Bristol-Myers Squibb
  • Erbitux
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc
  • OSI Pharmaceuticals Inc
  • Tarceva
  • Vectibix
目錄

According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $1.91 billion in 2017 and is expected to reach $4.96 billion by 2026 growing at a CAGR of 11.2% during the forecast period. Factors such as increasing special drug designation, proven efficacy of EGFR inhibitors and the growing prevalence of cancer indications are fuelling the market growth. However, prevent cell growth would be hindered by all participants receiving EGFR.

The Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it. EGFR is found at abnormally high levels in cancer cells, and EGFR activation appears to be important in tumour growth and progression. Some types of cancers show mutations in their EGFRs, which may cause unregulated cell division through continual or abnormal activation of the EGFR. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-regulation, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and colon cancer.

Based on indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, and others. Lung cancer is the leading cause of cancer-related death in both men and women in the United States, and the median 5-year survival rate for lung cancer is 5% worldwide.1 Lung cancer is divided into 2 major categories based on histological features: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which constitute 15% and 85% of lung cancer cases, respectively. By Geography, North American region led the epidermal growth factor receptor inhibitors market. The growth of the epidermal growth factor receptor inhibitors market in North America can be attributed to factors such as the increasing prevalence of the various types of major cancer indications, heavy sales of approved therapeutics, and the presence of various patient programs from both the vendors and the governments in the region.

Some of the key players profiled in the Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Amgen Inc, Bristol-Myers Squibb, Erbitux, F. Hoffmann-La Roche Ltd, Genentech, Inc, OSI Pharmaceuticals Inc, Tarceva and Vectibix.

Indications Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others Indications

Blocking Drugs Covered:

  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors (TKI)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market, By Indication

  • 5.1 Introduction
  • 5.2 Breast Cancer
  • 5.3 Colorectal Cancer
  • 5.4 Lung Cancer
  • 5.5 Others Indications

6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market, By Blocking Drug

  • 6.1 Introduction
  • 6.2 Monoclonal Antibodies
    • 6.2.1 Cetuximab
    • 6.2.2 Necitumumab
  • 6.3 Tyrosine Kinase Inhibitors (TKI)
    • 6.3.1 Erlotinib
    • 6.3.2 Gefitinib

7 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Amgen Inc
  • 9.2 Bristol-Myers Squibb
  • 9.3 Erbitux
  • 9.4 F. Hoffmann-La Roche Ltd
  • 9.5 Genentech, Inc
  • 9.6 OSI Pharmaceuticals Inc
  • 9.7 Tarceva
  • 9.8 Vectibix

List of Tables

  • Table 1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Region (2016-2026) ($MN)
  • Table 2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 7 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 8 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 9 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 10 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 11 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 12 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 13 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)
  • Table 14 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Country (2016-2026) ($MN)
  • Table 15 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 16 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 17 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 18 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 19 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 20 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 21 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 22 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 23 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 24 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 25 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 26 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)
  • Table 27 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Country (2016-2026) ($MN)
  • Table 28 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 29 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 30 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 31 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 32 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 33 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 34 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 35 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 36 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 37 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 38 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 39 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)
  • Table 40 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Country (2016-2026) ($MN)
  • Table 41 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 42 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 43 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 44 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 45 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 46 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 47 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 48 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 49 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 50 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 51 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 52 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)
  • Table 53 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Country (2016-2026) ($MN)
  • Table 54 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 55 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 56 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 57 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 58 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 59 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 60 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 61 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 62 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 63 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 64 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 65 South America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)
  • Table 66 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Country (2016-2026) ($MN)
  • Table 67 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Indication (2016-2026) ($MN)
  • Table 68 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Breast Cancer (2016-2026) ($MN)
  • Table 69 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
  • Table 70 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Lung Cancer (2016-2026) ($MN)
  • Table 71 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Others Indications (2016-2026) ($MN)
  • Table 72 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Blocking Drug (2016-2026) ($MN)
  • Table 73 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • Table 74 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Cetuximab (2016-2026) ($MN)
  • Table 75 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Necitumumab (2016-2026) ($MN)
  • Table 76 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Tyrosine Kinase Inhibitors (TKI) (2016-2026) ($MN)
  • Table 77 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Erlotinib (2016-2026) ($MN)
  • Table 78 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook, By Gefitinib (2016-2026) ($MN)